Grufity logo
Grufity logo

Latest SUPERSTRING CAPITAL MANAGEMENT LP Stock Portfolio

$158Million | No. of Holdings #32

SUPERSTRING CAPITAL MANAGEMENT LP Performance

2026 Q2+20.44%
YTD+19.27%
2025+60.47%

About SUPERSTRING CAPITAL MANAGEMENT LP and 13F Hedge Fund Stock Holdings

On 2026-08-14, the fund reported it's updated stock portfolio. In the 13F Holdings report, SUPERSTRING CAPITAL MANAGEMENT LP reported an equity portfolio of $158.4 Millions as of 30 Jun, 2026. <br><br> The top stock holdings of SUPERSTRING CAPITAL MANAGEMENT LP are COGT, AXSM, GMAB. The fund has invested 8.4% of it's portfolio in COGENT BIOSCIENCES INC and 8.3% of portfolio in AXSOME THERAPEUTICS INC. <br><br> The fund managers got completely rid off SUMMIT THERAPEUTICS INC (SMMT), VERTEX PHARMACEUTICALS INC (VRTX) and IQVIA HLDGS INC (IQV) stocks. They significantly reduced their stock positions in SIONNA THERAPEUTICS INC, UROGEN PHARMA LTD (URGN) and ZAI LAB LTD (ZLAB). SUPERSTRING CAPITAL MANAGEMENT LP opened new stock positions in REVOLUTION MEDICINES INC (RVMD), BEONE MEDICINES LTD (BGNE) and CYBIN INC (CYBN). The fund showed a lot of confidence in some stocks as they added substantially to AXSOME THERAPEUTICS INC. (AXSM), ORIC PHARMACEUTICALS INC (ORIC) and CLIMB BIO INC (ELYM).
SUPERSTRING CAPITAL MANAGEMENT LP Equity Portfolio Value
Last Reported on: 14 Aug, 2026
$158Million
  as of Aug 14, 2026

SUPERSTRING CAPITAL MANAGEMENT LP Annual Return Estimates Vs S&P 500

Our best estimate is that SUPERSTRING CAPITAL MANAGEMENT LP made a return of 20.44% in the last quarter. In trailing 12 months, it's portfolio return was 86.22%.
  • Performance
  • S&P 500

New Buys

Ticker$ Bought
revolution medicines inc9,561,210
beone medicines ltd3,497,440
cybin inc1,351,240
kiniksa pharmaceuticals intl1,206,540
roivant sciences ltd906,798
faeth therapeutics inc354,375
boundless bio inc138,390
vyne therapeutics inc39,868
New stocks bought by SUPERSTRING CAPITAL MANAGEMENT LP

Additions

Ticker% Inc.
axsome therapeutics inc.380
oric pharmaceuticals inc252
climb bio inc161
bright minds biosciences inc128
genmab a/s118
trevi therapeutics inc108
celldex therapeutics inc new59.73
cogent biosciences inc52.46
Additions to existing portfolio by SUPERSTRING CAPITAL MANAGEMENT LP

Reductions

Ticker% Reduced
sionna therapeutics inc-55.22
urogen pharma ltd-50.61
definium therapeutics inc-46.43
zai lab ltd-43.51
immunovant inc-41.73
vaxcyte inc-39.53
savara inc-38.37
maplight therapeutics inc-34.72
SUPERSTRING CAPITAL MANAGEMENT LP reduced stake in above stock

Sold off

Ticker$ Sold
summit therapeutics inc -16,928,900
arvinas inc -3,313,770
taysha gene therapies inc -1,154,460
century therapeutics inc -269,636
travere therapeutics inc -3,052,820
pfizer inc -2,077,920
oruka therapeutics inc -3,119,140
cullinan therapeutics inc -845,268
SUPERSTRING CAPITAL MANAGEMENT LP got rid off the above stocks

Sector Distribution

SUPERSTRING CAPITAL MANAGEMENT LP has about 75.3% of it's holdings in Healthcare sector.

  • Healthcare
  • Others
Sector%
Healthcare75.3
Others24.7

Market Cap. Distribution

SUPERSTRING CAPITAL MANAGEMENT LP has about 21.5% of it's portfolio invested in the large-cap and mega-cap stocks.

  • MID-CAP
  • UNALLOCATED
  • SMALL-CAP
  • LARGE-CAP
  • MICRO-CAP
  • MEGA-CAP
Category%
MID-CAP28.8
UNALLOCATED24.7
SMALL-CAP19.6
LARGE-CAP19.3
MICRO-CAP5.1
MEGA-CAP2.2

Stocks belong to which Index?

About 62.8% of the stocks held by SUPERSTRING CAPITAL MANAGEMENT LP either belong to S&P 500 or RUSSELL 2000 index.

  • RUSSELL 2000
  • Others
Index%
RUSSELL 200062.8
Others37.2
Top 5 Winners (%)%
definium therapeutics inc
114.3 %
URGN
urogen pharma ltd
78.2 %
maplight therapeutics inc
63.0 %
adlai nortye ltd
53.5 %
ELYM
climb bio inc
48.8 %
Top 5 Winners ($)$
definium therapeutics inc
7.6 M
URGN
urogen pharma ltd
5.4 M
IMVT
immunovant inc
3.9 M
TRVI
trevi therapeutics inc
2.6 M
AXSM
axsome therapeutics inc.
2.5 M
Top 5 Losers (%)%
BMEA
biomea fusion inc
-77.7 %
TARA
protara therapeutics inc
-26.7 %
ORIC
oric pharmaceuticals inc
-9.8 %
UTHR
united therapeutics corp del
-7.5 %
TNXP
tonix pharmaceuticals hldg c
-7.2 %
Top 5 Losers ($)$
ORIC
oric pharmaceuticals inc
-0.5 M
UTHR
united therapeutics corp del
-0.3 M
BMEA
biomea fusion inc
-0.3 M
TARA
protara therapeutics inc
-0.2 M
TNXP
tonix pharmaceuticals hldg c
-0.1 M

SUPERSTRING CAPITAL MANAGEMENT LP Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of SUPERSTRING CAPITAL MANAGEMENT LP

SUPERSTRING CAPITAL MANAGEMENT LP has 32 stocks in it's portfolio. About 63.8% of the portfolio is in top 10 stocks. ORIC proved to be the most loss making stock for the portfolio. was the most profitable stock for SUPERSTRING CAPITAL MANAGEMENT LP last quarter.

$158.38MTotal Value
43.00Positions
14 Aug, 2026Last Reported
Current holdings of Current Stock Holdings of SUPERSTRING CAPITAL MANAGEMENT LP, last reported on 14 Aug, 2026. Select a row with a linked ticker to view its historical trend.
ExpandHoldingsorted ascending% PortfolioShares Held$ Value% Change
CYBN
Cybin Inc

Cybin Inc

CYBN
SUPERSTRING CAPITAL MANAGEMENT LP's holding in Cybin Inc over time
0.85%204,424
$1.35M
0.85%
new position
DRUG
Bright Minds Biosciences Inc

Bright Minds Biosciences Inc

DRUG
SUPERSTRING CAPITAL MANAGEMENT LP's holding in Bright Minds Biosciences Inc over time
1.35%30,456
$2.14M
1.35%
increased 128.8 percentadded
GMAB
Genmab A/S

Genmab A/S

GMAB
SUPERSTRING CAPITAL MANAGEMENT LP's holding in Genmab A/S over time
7.47%430,600
$11.83M
7.47%
increased 118.9 percentadded